The Rituximab Biosimilars Market has fundamentally altered the competitive dynamics of the CD20-targeted therapy space. Roche, the originator of Rituxan/MabThera, has seen its monopoly erode as multiple biosimilars have entered key markets, particularly in Europe and the United States.

Celltrion’s Truxima, the world’s first oncology biosimilar of Rituxan, was launched in the U.S. in late 2019 and has maintained a 30 percent market share, with the company expected to pursue further gains following its recent label expansion. In Europe, Truxima has similarly captured a 30 percent market share as of 2024, according to Celltrion’s earnings report. Pfizer’s Ruxience and Amgen’s Riabni have also gained traction, though with varying degrees of success due to differences in their approved indications.

The impact on Roche has been substantial. In the U.S. alone, annual sales of Rituxan were in the region of USD 4.3 billion before biosimilar entry, but the drug has already seen sales fall dramatically in Europe thanks to biosimilar competition. Post-patent expiry, the branded rituximab market faces revenue erosion due to aggressive biosimilar pricing, with estimates suggesting a 30-50% decline in high-uptake regions.

In response, Roche has emphasized lifecycle management strategies, including the development of subcutaneous formulations, expansion into emerging indications, and ongoing clinical trials to maintain its market leadership. The company has also engaged in strategic collaborations and pricing adjustments to defend its market share.

The competitive landscape is further complicated by the emergence of next-generation anti-CD20 therapies, including obinutuzumab (Gazyva), which offers improved efficacy in certain indications. These novel agents, while more expensive, may capture share from both originator rituximab and its biosimilars in the long term.

For biosimilar manufacturers, success hinges on several factors: securing broad label indications, obtaining interchangeability status, building strong relationships with payers and providers, and achieving manufacturing scale to drive down costs. Celltrion’s ability to match Rituxan’s label across most adult indications has been a key competitive advantage, while Pfizer’s Ruxience has lagged due to its narrower approved uses.

As the market continues to evolve, the differentiation between biosimilars will increasingly be based on non-clinical factors such as supply chain reliability, patient support programs, and contracting terms. The companies that can best meet the needs of healthcare systems facing mounting financial pressures will emerge as leaders in this USD 11.78 billion market by 2035.